A virus is administered to cancer patients with the aim of boosting their body’s immune response. This approach enables patients to better combat the tumor and potentially extend their lifespan, as reported by Clinical Cancer Research.
The virus, designated “Delta-24-RGD,” is directly injected into the tumor, where it targets cancer cells while leaving healthy cells unharmed.
Clinical trials have substantiated the anti-tumor efficacy of this method, with most participants showing improved tumor responsiveness to treatment. Blood samples were collected from these individuals. Researchers identified biomarkers that indicate the immune system’s readiness to fight cancer.
Blood analysis helps determine which cancer patients would benefit from additional viral administration to aid their bodies in combating brain tumors.
About the Author
